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Many may not be aware of the full extent of global inequity in the rollout of Coronavirus Dis-
ease 2019 (CAU : PleasenotethatCOVID   19hasbeendefinedasCoronavirusDisease2019inthesentenceManymaynotbeawareofthe::::Pleasecheckandcorrectifnecessary:OVID-19) vaccines in response to the S vere Acute Respir tory Syndrome Coro-
navirus 2 (SAU : PleasenotethatSARS   CoV   2hasbeendefinedasSevereAcuteRespiratorySyndromeCoronavirus2inthesentenceManymaynotbeawareofthe::::Pleasecheckandcorrectifnecessary:RS-CoV-2) pandemic. As of June 20, 2021, only 0.9% of those living in low-
income countries and less than 10% of those in lAU : Pleasenotethatlow   andlowermiddle   incomecountrieshasbeenchangedtolow   andmiddle   incomecountriesinthesentenceAsofJune20; 2021; only0:9%ofthose::::Pleasecheckandcorrectifnecessary:ow- and middle-income cou tries (LMICs)
had received at least 1 dose of a COVID-19 vaccine compared with 43% of the population liv-
ing in high-income countries (HICs) [1] (Fig 1). Only 2.4% of the population of Africa had
been vaccinated compared with 41% of North America and 38% of Europe [1,2] (S1 Fig). Pri-
marily due to the inability to access COVID-19 vaccines, less than 10% of the population in as
many as 85 LMICs had been vaccinated compared with over 60% of the population in 26 HICs
[1]. Only 10 countries account for more than 75% of all COVID-19 vaccines administered [3].
This striking and ongoing inequity has occurred despite the explicit ethical principles affirm-
ing equity of access to COVID-19 vaccines articulated in WHO SAGE values framework [4,5]
prepared in mid-2020, well prior to the availability of COVID-19 vaccines.
The COVID-19 pandemic highlights the grave inequity and inadequacy of the global pre-
paredness and response to serious emerging infections. The establishment of the Coalition for
Epidemic Preparedness Innovations (CEPI) in 2018, the Access to COVID-19 Tools Accelera-
tor (ACT-A), and the COVID-19 Vaccines Global Access (COVAX) Facility in April 2020 and
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the rapid development of COVID-19 vaccines were all positive and extraordinary develop-
ments [6]. The COVAX Facility, as of June 2021, has delivered approximately 83 million vac-
cine doses to 75 countries, representing approximately 4% of the global supply, and one-fifth
of this was for HICs [7]. The COVAX Facility has been challenged to meet its supply commit-
ments to LMICs due to insufficient access to doses of COVID-19 vaccines with the prerequisite
WHO emergency use listing (EUL) or, under exceptional circumstances, product approval by
a stringent regulatory authority (SRA) [8,9]. Because of the anticipated insufficient COVID-19
vaccine supply through the COVAX Facility, the majority of nonvaccine-producing LMIC
countries made the decision, early in the COVID-19 pandemic, to secure and use vaccines pro-
duced in China or Russia prior to receipt of WHO EUL or SRA approval. Most of the vaccines
used in LMICs as of June 20, 2021 (nearly 1.5 billion doses of the 2.6 billion doses adminis-
tered) were neither WHO EUL or SRA approved at the time they were given [10]. This may
raise possible concerns with respect to the effectiveness, safety, and acceptability of individual
vaccines used by many countries [8,9].
GAU : Pleaseconfirmthatallheadinglevelsarerepresentedcorrectly:7 leaders fall short
Although the recent declaration of G7 leaders to donate 1 billion vaccine doses [11] over the
next year was welcome news, the donation falls far short of the more than 11 billion doses
WHO estimates are required to accelerate control of the pandemic and avert millions of pre-
ventable deaths globally due to COVID-19. The G7 leaders failed to lead or even initiate a
meaningful roadmap, nor pledge the necessary resources to support the implementation, to
accelerate global access and equity to COVID-19 vaccines, in addition to other measures to
reduce mortality and control the pandemic. While HICs contributed to the formation and
funding of COVAX and the COVAX Facility responsible for equitable global access of
COVID-19 vaccines, bilateral contracts with the pharmaceutical companies have monopolized
most of the available vaccines [2,12]. A stark example is the case of the Indian vaccine manu-
facturers, which had to redirect their previously committed vaccine supplies to address the
massive surge of COVID-19 cases in India during the second quarter of 2021 [2].
An international initiative to support vaccine technology transfer is
needed
The governments of South Africa and India have called for the waiver of intellectual property
protections for patents, industrial designs, trade secrets, and regulatory data for COVID-19
vaccines and therapies. The United States President Biden supported the Trade-Related
Aspects of Intellectual Property Rights (TRIPS) waiver call as have China and Russia [12,13].
Of urgent critical importance, however, is technology transfer to enable more vaccine manu-
facturers to produce vaccines under license from the vaccine originators, largely pharmaceuti-
cal companies. Along these lines, the World Trade Organization (WTO) has proposed the use
of voluntary licensing arrangements, led by public–private partnerships, that would enable the
transfer of high-quality know-how needed to produce safe, high-quality, and effective vaccines
[14]. For this to be successful, there must be a fully funded, internationally coordinated initia-
tive that facilitates technology transfer, building of vaccine manufacturing, scientific and regu-
latory capacity in different regions, and a genuine commitment to working collectively in the
common interest that transcends national boundaries and narrow interests [13,15,16].
Improve vaccine access to low- and middle-income countries
While international capacity building and strengthening is essential, we also must redouble the
efforts to leave no one behind by providing COVID-19 vaccine access to all the world’s LMIC
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populations now. Many HICs can make more vaccine doses available sooner than promised
without compromising their ability to vaccinate their own populations. This requires a
2-pronged initiative. First, maximize vaccine donations from HICs and the pharmaceutical
companies through COVAX. Countries such as the US could step up their efforts by leveraging
US funding and resources to enhance the impact of COVAX and support a roadmap for
immediate distribution of currently unallocated or reserve doses of vaccines [17,18]. Second,
embark on a parallel initiative to ramp up production and distribution capacity for additional
doses of vaccines. Based on the estimated 3 billion people who live in LMICs, this means the
scale-up and manufacture of 6 billion doses, preferably during 2021 [19]. For this to happen,
we need a full inventory of all mRNA and adenovirus-vectored vaccines currently available,
understand the commitments to produce more of these vaccines in the coming months, and
then fill that substantial gap with new recombinant protein-based vaccines now being pro-
duced in India, China, US/Europe, and elsewhere [10,20–22]. Such recombinant protein-
based vaccines can be easily scaled up and delivered, with prospects of high efficacy against the
variants of concern, as seen with at least 1 protein-based vaccine [23]. This step is essential to
halt the spread of variants globally and the high death tolls anticipated in Africa, Latin Amer-
ica, and Southeast Asia.
A few high-income or well-positioned middle-income countries have made significant
progress in vaccinating their populations; however, the global response to the COVID-19 pan-
demic continues to fall gravely short of what is possible and required to reduce mortality and
morbidity. Until urgent measures are taken, the most vulnerable living in LMICs will remain
excluded from global health progress, exacerbating inequities (Box 1). It is important to recog-
nize that the bulk of vaccines now in use would not have been developed without significant
governmental and multilateral investments. Moving forward, we need sustainability, with sub-
stantial pandemic preparedness funding for international agencies to support global public
Fig 1. Proportion of people vaccinated with at least 1 dose of COVID-19 vaccine by income (April 14 to June 23, 2021). Note: Data on China appeared
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health and research. Governments should preserve a share in the patents of pharmaceutical
companies when government support has made a tangible contribution to the development of
the product being patented. At the same time, people in LMIC need to hold their leaders more
accountable to ensure that they advocate and negotiate on their behalf more effectively and
form alliances that can make meaningful gains. Key stakeholders must continue to learn the
lessons, forge new initiatives and partnerships, and advocate for tangible actions that promote
greater equity, justice, and solidarity.
Supporting information
S1 Fig. Proportion of people vaccinated with at least 1 dose of COVID-19 vaccine by conti-
nent (April 14 to June 23, 2021). Note: Data on China appeared on the database on June 9,
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